Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,339.00up ₹39.00 (1.70%)BSE ₹2,333.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹2,300.00.
29 Oct: open ₹2,311.00, high ₹2,339.00, low ₹2,295.30
52-week range of traded prices to 29 Oct 2026
₹1,798.60Low, 29 Oct 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹66,012 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.72
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.65
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,32,39638.7% delivered
Glenmark Pharmaceuticals disputes and clarifications
20 filed, newest first.
May 2019
13 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned- titled "Pharma stocks bleed as US states file lawsuit against generic drug firms". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company was aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Mar 2019
6 Mar · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to announcement dated 14-Feb-2019, regarding Board meeting held on February 14, 2019.". On basis of above the Company is required to clarify following: 1. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.2. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";3. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.4. Consideration received from such sale/disposal;5. The expected date of completion of sale/disposal;6. Date on which the agreement for sale has been entered into;7. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;The response of the Company is awaited.
Sep 2018
Aug 2018
10 Aug · Legal
Exchange has sought clarification from the Company with respect to news item captioned- True North in talks to buy into Glenmark API biz for Rs 1500 crIn this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Jul 2018
May 2018
4 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned- "Glenmark drug test under lens" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Feb 2017
2 Feb · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to announcement dated 02-Feb-2017, regarding the appointment of Mr. Harish Kuber (ACS 10973) as the Company Secretary and Compliance Officer of the Company with effect from February 02, 2017 upon the recommendation of the Nomination and Remuneration Committee. ". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Apr 2016
Jan 2016
5 Jan · Legal
Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Roche, Glenmark Settle Patent suit over cancer drug". The Company, has vide email dated January 04, 2016 has submitted that Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride. As part of the agreement, the companies have ceased all relevant patent litigation on this product. The settlement is a part of normal course of our business and it will have no material impact on the company.4 Jan · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Roche, Glenmark Settle Patent suit over cancer drug' . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
Mar 2015
20 Mar · Legal
Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to a news item captioned "Delhi High court restrains Glenmark Pharma from manufacturing and marketing Zeta, Zeta-met used to treat Diabeties". The Company has clarified that "Division bench of Delhi high court has injuncted on March 20, 2015 Glenmark from manufacturing Zita and Zita- met. The injunction is not applicable for the products (zita and zita-met) which are already in market. The company is seeking legal advise on the next steps and will take appropriate action".20 Mar · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Delhi High court restrains Glenmark Pharma from manufacturing and marketing Zeta, Zeta-met used to treat Diabeties". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Feb 2015
27 Feb · Legal
Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Glenmark to set up new plant in US". The Company has clarified that, it is the same plant with respect to which press release intimating the setting up of the plant was issued on July 17, 2014.27 Feb · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Glenmark to set up new plant in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
29 Dec · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with reference to recent news item captioned "Glenmark to out-licence molecule". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The reply from the Company is Awaited.